Akero Therapeutics, Inc. (AKRO) News
Filter AKRO News Items
AKRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKRO News Highlights
- For AKRO, its 30 day story count is now at 9.
- Over the past 17 days, the trend for AKRO's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- EFX and KPTI are the most mentioned tickers in articles about AKRO.
Latest AKRO News From Around the Web
Below are the latest news stories about Akero Therapeutics Inc that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsAkero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year |
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Karyopharm Therapeutics (KPTI) H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $26.00. The company's shares closed last Wednesday at $9.13. According to TipRanks. |
Akero finishes enrollment in phase 2b trial of efruxifermin in liver diseaseAkero Therapeutics (AKRO -0.2%) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin (EFX) to treat non-alcoholic steatohepatitis (NASH). "Our confidence in EFX’s potential is based on Phase 2a data that showed substantial rates of fibrosis regression after only 16 weeks of treatment. We believe the larger Phase 2b HARMONY... |
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH PatientsSOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH). |
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year. |
Akero Therapeutics (AKRO) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceNo summary available. |
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Compa |
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of Buy from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus recommendation of Buy from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued [] |
Investment Analysts Weekly Ratings Changes for Akero Therapeutics (AKRO)Akero Therapeutics (NASDAQ: AKRO) recently received a number of ratings updates from brokerages and research firms: 11/16/2021 Akero Therapeutics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $29.00 price target on the stock. According to Zacks, Akero Therapeutics Inc. is a clinical-stage [] |
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual ConferenceSOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T. A live webcast of the Company fireside chat will be available through the investor relatio |